A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients (MAESTRO-NAFLD1)
A 52-Week, Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD) (MAESTRO-NAFLD-1)
Sponsor: Madrigal Pharmaceuticals, Inc.
Listed as NCT04197479, this PHASE3 trial focuses on Non-Alcoholic Fatty Liver Disease and remains completed. Sponsored by Madrigal Pharmaceuticals, Inc., it has been updated 11 times since 2019, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Oct 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Sep 2023 — Oct 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 6 earlier versions
-
Sep 2022 — Sep 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2021 — Sep 2022 [monthly]
Recruiting PHASE3
-
Aug 2020 — Jan 2021 [monthly]
Recruiting PHASE3
-
Jun 2020 — Aug 2020 [monthly]
Recruiting PHASE3
-
Apr 2020 — Jun 2020 [monthly]
Recruiting PHASE3
-
Jan 2020 — Apr 2020 [monthly]
Recruiting PHASE3
First recorded
Dec 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Madrigal Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .